COMPARISON OF MEAN PLATELET MASS AND MEAN PLATELET COMPONENT IN IMMUNE THROMBOCYTOPENIA, HYPOPROLIFERATIVE THROMBOCYTOPENIAS, AND HEALTHY INDIVIDUALS
(Abstract release date: 05/19/16)
EHA Library. Melinscak H. 06/09/16; 132981; E1432
Dr. Hrvoje Melinscak
Contributions
Contributions
Abstract
Abstract: E1432
Type: Eposter Presentation
Background
Immune thrombocytopenia (ITP) remains a diagnosis of exclusion. The Siemens ADVIA 120 has the capacity to calculate the mean platelet (PLT) component (MPC), a measure of PLT density, and the mean platelet mass (MPM), neither of which are currently employed in clinical decision making.
Aims
To determine if the MPC and MPM are significantly higher in ITP (reflecting increased PLT granules) than in hypoproliferative thrombocytopenia (HT) and in the healthy population.
Methods
Institutional review board approval was obtained. A prospective study was initiated in September 2013. This trial is registered at ClinicalTrials.gov. Patients at Mount Sinai Roosevelt Hospital with ITP, as defined by the ASH 2011 practice guidelines, and HT's (delineated in Results section) were included. A reference population was established. Patients with human immunodeficiency virus, hepatitis C, cirrhosis, pregnancy, and disseminated intravascular coagulation were excluded. Enrollment of 20 patients in each arm and 10 healthy individuals in the control arm was planned. Lavender tri-potassium EDTA tubes were filled and analyzed on the Siemens ADVIA 120 within a period not exceeding 2 hours from their collection. MPC and MPM values were compared for all 3 groups using one-way analysis of variance. The student's t-test was used to compare these parameters in the patient groups.
Results
Twenty patients with ITP, 20 patients with HT (4 aplastic anemia, 8 chemotherapy-induced thrombocytopenia, 3 myelodysplasia, 1 acute myelogenous leukemia, 1 hairy cell leukemia, 1 multiple myeloma, and 2 drug-induced thrombocytopenia (valproic acid, imatinib)), and 10 controls were enrolled. Baseline characteristics of the patient groups were similar. Median age, M:F ratio, and mean PLT count were 54 years, 0.67:1, and 62,500/µL (ITP) and 60.5 years, 1:1, and 53,900/µL (HT), p>0.05. MPC (g/dL, mean +/- SD) for each group was 26.7 +/- 1.89 (ITP), 24.2 +/- 1.89 (HT), and 28.09 +/- 0.74 (controls), p < 0.01. MPM (pg, mean +/- SD) for each group was 2.43 +/- 0.451 (ITP), 1.95 +/- 0.210 (HT), and 1.91 +/- 0.10 (controls), p < 0.01. Comparison of these parameters for the 2 patient groups showed statistical significance (p < 0.01).
Conclusion
MPM is significantly higher in ITP than in HT and in controls, likely reflecting increased granular content. While MPC is significantly higher in ITP than in HT, it is highest in controls, etiology unclear. Future studies should further evaluate these parameters for distinguishing ITP from other thrombocytopenias.
Session topic: E-poster
Keyword(s): Aplastic anemia, Immune thrombocytopenia (ITP), Myelodysplasia, Platelet
Type: Eposter Presentation
Background
Immune thrombocytopenia (ITP) remains a diagnosis of exclusion. The Siemens ADVIA 120 has the capacity to calculate the mean platelet (PLT) component (MPC), a measure of PLT density, and the mean platelet mass (MPM), neither of which are currently employed in clinical decision making.
Aims
To determine if the MPC and MPM are significantly higher in ITP (reflecting increased PLT granules) than in hypoproliferative thrombocytopenia (HT) and in the healthy population.
Methods
Institutional review board approval was obtained. A prospective study was initiated in September 2013. This trial is registered at ClinicalTrials.gov. Patients at Mount Sinai Roosevelt Hospital with ITP, as defined by the ASH 2011 practice guidelines, and HT's (delineated in Results section) were included. A reference population was established. Patients with human immunodeficiency virus, hepatitis C, cirrhosis, pregnancy, and disseminated intravascular coagulation were excluded. Enrollment of 20 patients in each arm and 10 healthy individuals in the control arm was planned. Lavender tri-potassium EDTA tubes were filled and analyzed on the Siemens ADVIA 120 within a period not exceeding 2 hours from their collection. MPC and MPM values were compared for all 3 groups using one-way analysis of variance. The student's t-test was used to compare these parameters in the patient groups.
Results
Twenty patients with ITP, 20 patients with HT (4 aplastic anemia, 8 chemotherapy-induced thrombocytopenia, 3 myelodysplasia, 1 acute myelogenous leukemia, 1 hairy cell leukemia, 1 multiple myeloma, and 2 drug-induced thrombocytopenia (valproic acid, imatinib)), and 10 controls were enrolled. Baseline characteristics of the patient groups were similar. Median age, M:F ratio, and mean PLT count were 54 years, 0.67:1, and 62,500/µL (ITP) and 60.5 years, 1:1, and 53,900/µL (HT), p>0.05. MPC (g/dL, mean +/- SD) for each group was 26.7 +/- 1.89 (ITP), 24.2 +/- 1.89 (HT), and 28.09 +/- 0.74 (controls), p < 0.01. MPM (pg, mean +/- SD) for each group was 2.43 +/- 0.451 (ITP), 1.95 +/- 0.210 (HT), and 1.91 +/- 0.10 (controls), p < 0.01. Comparison of these parameters for the 2 patient groups showed statistical significance (p < 0.01).
Conclusion
MPM is significantly higher in ITP than in HT and in controls, likely reflecting increased granular content. While MPC is significantly higher in ITP than in HT, it is highest in controls, etiology unclear. Future studies should further evaluate these parameters for distinguishing ITP from other thrombocytopenias.
Session topic: E-poster
Keyword(s): Aplastic anemia, Immune thrombocytopenia (ITP), Myelodysplasia, Platelet
Abstract: E1432
Type: Eposter Presentation
Background
Immune thrombocytopenia (ITP) remains a diagnosis of exclusion. The Siemens ADVIA 120 has the capacity to calculate the mean platelet (PLT) component (MPC), a measure of PLT density, and the mean platelet mass (MPM), neither of which are currently employed in clinical decision making.
Aims
To determine if the MPC and MPM are significantly higher in ITP (reflecting increased PLT granules) than in hypoproliferative thrombocytopenia (HT) and in the healthy population.
Methods
Institutional review board approval was obtained. A prospective study was initiated in September 2013. This trial is registered at ClinicalTrials.gov. Patients at Mount Sinai Roosevelt Hospital with ITP, as defined by the ASH 2011 practice guidelines, and HT's (delineated in Results section) were included. A reference population was established. Patients with human immunodeficiency virus, hepatitis C, cirrhosis, pregnancy, and disseminated intravascular coagulation were excluded. Enrollment of 20 patients in each arm and 10 healthy individuals in the control arm was planned. Lavender tri-potassium EDTA tubes were filled and analyzed on the Siemens ADVIA 120 within a period not exceeding 2 hours from their collection. MPC and MPM values were compared for all 3 groups using one-way analysis of variance. The student's t-test was used to compare these parameters in the patient groups.
Results
Twenty patients with ITP, 20 patients with HT (4 aplastic anemia, 8 chemotherapy-induced thrombocytopenia, 3 myelodysplasia, 1 acute myelogenous leukemia, 1 hairy cell leukemia, 1 multiple myeloma, and 2 drug-induced thrombocytopenia (valproic acid, imatinib)), and 10 controls were enrolled. Baseline characteristics of the patient groups were similar. Median age, M:F ratio, and mean PLT count were 54 years, 0.67:1, and 62,500/µL (ITP) and 60.5 years, 1:1, and 53,900/µL (HT), p>0.05. MPC (g/dL, mean +/- SD) for each group was 26.7 +/- 1.89 (ITP), 24.2 +/- 1.89 (HT), and 28.09 +/- 0.74 (controls), p < 0.01. MPM (pg, mean +/- SD) for each group was 2.43 +/- 0.451 (ITP), 1.95 +/- 0.210 (HT), and 1.91 +/- 0.10 (controls), p < 0.01. Comparison of these parameters for the 2 patient groups showed statistical significance (p < 0.01).
Conclusion
MPM is significantly higher in ITP than in HT and in controls, likely reflecting increased granular content. While MPC is significantly higher in ITP than in HT, it is highest in controls, etiology unclear. Future studies should further evaluate these parameters for distinguishing ITP from other thrombocytopenias.
Session topic: E-poster
Keyword(s): Aplastic anemia, Immune thrombocytopenia (ITP), Myelodysplasia, Platelet
Type: Eposter Presentation
Background
Immune thrombocytopenia (ITP) remains a diagnosis of exclusion. The Siemens ADVIA 120 has the capacity to calculate the mean platelet (PLT) component (MPC), a measure of PLT density, and the mean platelet mass (MPM), neither of which are currently employed in clinical decision making.
Aims
To determine if the MPC and MPM are significantly higher in ITP (reflecting increased PLT granules) than in hypoproliferative thrombocytopenia (HT) and in the healthy population.
Methods
Institutional review board approval was obtained. A prospective study was initiated in September 2013. This trial is registered at ClinicalTrials.gov. Patients at Mount Sinai Roosevelt Hospital with ITP, as defined by the ASH 2011 practice guidelines, and HT's (delineated in Results section) were included. A reference population was established. Patients with human immunodeficiency virus, hepatitis C, cirrhosis, pregnancy, and disseminated intravascular coagulation were excluded. Enrollment of 20 patients in each arm and 10 healthy individuals in the control arm was planned. Lavender tri-potassium EDTA tubes were filled and analyzed on the Siemens ADVIA 120 within a period not exceeding 2 hours from their collection. MPC and MPM values were compared for all 3 groups using one-way analysis of variance. The student's t-test was used to compare these parameters in the patient groups.
Results
Twenty patients with ITP, 20 patients with HT (4 aplastic anemia, 8 chemotherapy-induced thrombocytopenia, 3 myelodysplasia, 1 acute myelogenous leukemia, 1 hairy cell leukemia, 1 multiple myeloma, and 2 drug-induced thrombocytopenia (valproic acid, imatinib)), and 10 controls were enrolled. Baseline characteristics of the patient groups were similar. Median age, M:F ratio, and mean PLT count were 54 years, 0.67:1, and 62,500/µL (ITP) and 60.5 years, 1:1, and 53,900/µL (HT), p>0.05. MPC (g/dL, mean +/- SD) for each group was 26.7 +/- 1.89 (ITP), 24.2 +/- 1.89 (HT), and 28.09 +/- 0.74 (controls), p < 0.01. MPM (pg, mean +/- SD) for each group was 2.43 +/- 0.451 (ITP), 1.95 +/- 0.210 (HT), and 1.91 +/- 0.10 (controls), p < 0.01. Comparison of these parameters for the 2 patient groups showed statistical significance (p < 0.01).
Conclusion
MPM is significantly higher in ITP than in HT and in controls, likely reflecting increased granular content. While MPC is significantly higher in ITP than in HT, it is highest in controls, etiology unclear. Future studies should further evaluate these parameters for distinguishing ITP from other thrombocytopenias.
Session topic: E-poster
Keyword(s): Aplastic anemia, Immune thrombocytopenia (ITP), Myelodysplasia, Platelet
{{ help_message }}
{{filter}}